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Background: The purpose of this study was to evaluate the survival outcome for middle ear cancer and to
construct prognostic models to provide patients and clinicians with more accurate estimates of individual
survival probability.
Methods: Patients diagnosed with middle ear cancer between 1983 and 2011 were selected for the study from the
Surveillance Epidemiology and End Results Program. We used the Kaplan-Meier product limit method to describe
overall survival and cause-specific survival. Cox proportional hazards models were fitted to model the relationships
between patient characteristics and prognosis. Nomograms for predicting overall survival and cause-specific survival
were built using the Cox models established.
Results: The entire cohort comprised 247 patients with malignant middle ear cancer. Median duration of follow-up
until censoring or death was 25 months (range, 1–319 months). Five-year overall survival and cause-specific survival
were 47.4% (95% Confidence Interval (CI), 41.2% to 54.6%) and 58.0% (95% CI, 51.6% to 65.3%), respectively. In
multivariable analysis, age, histological subtype, stage, surgery and radiotherapy were predictive of survival. The
bootstrap corrected c-index for model predicting overall and cause-specific survival was 0.73 and 0.74, respectively.
Calibration plots showed that the predicted survival reasonably approximated observed outcomes.
Conclusion: The models represent an objective analysis of all currently available data. The resulting models
demonstrated good accuracy in predicting overall survival and cause-specific survival. Nomograms should thus be
considered as a useful tool for predicting clinical prognosis.
Keywords: Middle ear cancer, Nomogram, Overall survival, Cause-specific survivalBackground
Malignant tumors of the temporal bone are rare and
account for <0.2% of all tumors of the head and neck [1].
The most common tumors include squamous cell carci-
noma (SCC), adenocarcinoma, basal cell carcinoma, ade-
noid cystic carcinoma, rhabdomyosarcoma, and Langerhans
histocytosis X (LHX). Primary carcinoma of the middle ear
represents a small subset of temporal bone carcinomas [2].* Correspondence: yo-r@ncchd.go.jp
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unless otherwise stated.The incidence of middle ear cancer was approximately 0.18
per million people in the United States in 2011, according
to the Surveillance Epidemiology and End Results (SEER)
[3]. The diagnosis is often delayed because the disease may
be masked by other ear symptoms. The complex anatomy
of the temporal bones, delayed presentation and diagnosis
make the surgical management difficult [1]. Although treat-
ment has been improving over the decades, the prognosis
remains poor [4].
Because of the rarity of malignant tumors of the middle
ear, most reports published previously were based on case
series from a single institution, and most of the literature
does not separate carcinomas of the external auditory
canal from primary carcinomas of the middle ear [2]. The
prognostic results therefore lack uniformity. To maked. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart for creation of the Surveillance
Epidemiology and End Results (SEER) data set.
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cancer, we should improve our understanding of this
disease process.
The SEER is a large population-based database that
has been used to provide epidemiological and prognos-
tic information about many types of cancers. Using a
population-based database can avoid the limitations of a
small sample size and the selection or treatment bias
associated with analysis of a single institution’s clinical
data. The purpose of this study was to evaluate the sur-
vival outcomes of middle ear cancer using the SEER data-
base. We also developed simple nomograms based on the
prognostic models established.
Methods
The SEER program of the National Cancer Institute is the
largest population-based cancer registry in the United
States. The SEER registries collect data on patient demo-
graphics, primary tumor site, stage, tumor morphology,
and treatment for all cancer patients, covering approxi-
mately 28% of the US population. For this research, the
recently released SEER (1973–2011) database was used for
case extraction [5]. All patients diagnosed with middle ear
cancer as their first malignancy were selected (site code
C30.1). Patients were excluded from the study if the tumor
was identified on the death certificate only. Middle ear
lymphomas and rhabdomysarcomas were also excluded.
Because there is no SEER stage information before 1983,
we also excluded patients diagnosed between 1973 and
1982. Detailed data selection is shown in Figure 1.
Variables in the analysis included: age at diagnosis;
sex; race; year of diagnosis; histological subtype; cancer
stage; surgery and radiotherapy. The American Joint
Committee on Cancer (AJCC) has not yet produced a
staging system for ear and temporal bone cancer. Here,
the clinical stage of cancer was grouped using the
historical stage coded by SEER: ‘localized’ was defined
as a tumor confined to the organ; ‘regional’ was defined
as a neoplasm that had extended into surrounding
organs or tissues, or into regional lymph nodes or by a
combination of extension and regional lymph nodes,
and ‘distant’ was defined as a tumor that had spread to
parts of the body remote from the primary tumor. The
histological subtype was re-grouped as squamous cell
carcinoma, adenocarcinoma and others.
Missing values were imputed with the ‘tanscan’ func-
tion of the regression modeling strategies (rms) package
[6]. Patients in the cohort were followed for vital status
until the earliest of the following dates: death; last con-
tact if before December 31, 2011 or December 31, 2011
if the date of last contact was after December 31, 2011.
Median follow-up was defined as the median observed
survival time among all patients. We used the Kaplan-
Meier product limit method to describe overall survival(OS) and cause-specific survival (CSS). The Cox propor-
tional hazards model was fitted to model the relation-
ships between patient characteristics and survival.
Variables used for building the multivariate regression
model were chosen based on known clinically prognos-
tic factors and availability in the SEER registry. We
tested the proportional hazard assumption for each
variable in the model. The restricted cubic splines with
three knots at the 10%, 50% and 90% empirical quantiles
were fitted to model age variables. Interaction between
histological type and surgery was evaluated in the
model. To avoid overfitting, we used a backward model
selection technique based on Akaike information criterion
(AIC) to reduce variables in the model [6]. The Wald test
was conducted to find which predictors were significant in
the model. Nomograms were developed on plain paper
based on the reduced models.
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strap validation was performed to evaluate the performance
of the model. A concordance index (c-index) was calculated
by bootstrapping with 200 resamples to obtain an unbiased
estimate of the ability of the model to discriminate among
patients. Subsequently, we compared the predicted
probability of survival versus actual survival also using 200
bootstrap resamples.
All statistical analysis was performed using R version
3.0.0 software (Institute for Statistics and Mathematics,
Vienna, Austria; www.r-project.org) [7]. The R package
rms was used for modeling and developing the nomogram
[8]. All P values presented in this article were calculated
based on a two-sided statistical test.Table 1 Patient characteristics and 5-year survival
Patients
Characteristic No. %
All patients 247 -
Age
<50 years 68 27.5
50-69 years 94 38.1

























Abbreviations: OS Overall survival, CSS Cause-specific survival, CI Confidence IntervalResults
Overall and cause-specific survival
A total of 247 cases of middle ear cancer were eligible for
inclusion, and 143 patients died during the study period.
Of these, 97 of 143 deaths were classified as cause-specific
death. Table 1 shows patients and tumor characteristics.
Sixty-eight patients (27.5%) were younger than 50 years,
94 patients (38.1%) were 50 to 69 years, and 85 patients
(34.4%) were 70 years or older. Overall, 50.6% of the study
population was male, and 80.6% was white. Median patient
age was 63 years. Median follow-up for these patients was
25 months (range 1–319 months). Five-year OS and CSS
rates were 47.4% (95% confidence interval (CI), 41.2% to
54.6%) and 58.0% (95% CI, 51.6% to 65.3%), respectively.OS CSS
5 y (%) 95% CI 5 y (%) 95% CI
47.4 41.2-54.6 58.0 51.6-65.3
71.3 60.8-83.6 77.3 67.5-88.6
45.7 35.9-58.3 56.4 46.2-68.9
29.9 21.1-42.5 42.8 32.3-56.6
51.8 43.4-61.9 62.2 53.5-72.2
42.4 33.7-53.4 53.7 44.6-65.6
48.9 42.0-56.9 58.0 51.0-66.1
40.8 27.9-59.7 57.8 43.9-76.1
50.7 34.2-75.1 54.0 37.2-78.5
33.4 23.8-46.8 43.7 32.9-58.0
54.0 45.8-63.6 66.2 58.1-75.3
28.7 21.5-38.4 40.7 32.3-51.3
73.5 59.1-91.3 83.5 71.1-98.0
68.9 58.6-81.1 76.1 66.1-87.6
74.8 64.4-86.9 84.7 75.8-94.6
42.0 33.9-52.0 52.1 43.5-62.3
23.0 13.0-40.9 33.8 20.8-55.0
37.7 26.3-54.1 50.9 38.2-67.9
50.4 43.3-58.6 60.1 53.0-68.3
66.7 58.1-76.7 78.5 70.6-87.2
30.9 23.4-40.8 40.5 32.1-51.1
.
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in Table 1.
Prognosis was worse with increasing age. The 5-year
OS was 71.3% for younger patients, 45.7% for the sub-
group aged 50 to 69 years, and 29.9% for the oldest
group aged 70 years or older. The corresponding 5-year
CSS was 77.3%, 56.4% and 42.8% for these three age
groups. Over 60% of patients were diagnosed after 2000.
Prognosis was better in the most recent decade than in
periods before 2000. Five-year OS for patients diagnosed
between 2000 and 2011 was 54.0%, and CSS was 66.2%.
Squamous cell carcinoma was present in approximately
55.9% of all patients with the poorest prognosis. The five-
year survival rates were 28.7% and 40.7% for OS and CSS,
respectively. Other histological subtypes included adeno-
carcinoma (13.8%), and others (30.4%) with 5-year OS of
73.5%, and 68.9%; and CSS of 83.5% and 76.1%, respec-
tively. Distant disease exhibited the worst prognosis, with
5-year OS being 23.0%, compared with localized and
regional disease, with 5-year OS of 74.8% and 42.0%,
respectively. The 5-year CSS was 84.7%, 52.1% and 33.8%
for localized, regional and distant groups, respectively.Table 2 Univariate analyses of survival in patients with midd
Overall survival
Covariate HR 95% CI






Non White 1.10 0.73-1.64















Abbreviations: HR Hazard Ratio, CI Confidence Interval.
*P <0.05.Around 77% patients were treated by surgery. Five-
year OS was 50.4% with surgery and 37.7% without sur-
gery, and the corresponding 5-year CSS was 60.1% and
50.9%, respectively. Around 55% patients underwent
radiation. The 5-year OS was 30.9% and 66.7% for radi-
ation and no radiation, and 5-year CSS was 40.5% and
78.5%, respectively. Actuarial survival grouped by histo-
logical subtype, stage, treatment is shown in Figure 1.
Univariable and multivariable models
The unadjusted association with prognosis is listed in
Table 2. The results of multivariable models are shown
in Tables 3 and 4, which show both the full model and
the final model. The assumption of a proportional ha-
zard was supported. Results of models predicting OS
and CSS showed similar results. In the full model, statis-
tically significant covariates were age, histological sub-
type, stage, surgery and radiation, according to the Wald
test. Histological subtype showed a significant inter-
action effect with surgery. After model selection, age,
stage of tumor, histological type, surgery and radiation
treatment were left in the reduced models.le ear cancer
Cause-specific survival
P-value HR 95% CI P-value
<0.001* 2.17 1.53-3.08 <0.001*
1
0.46 1.27 0.85-1.90 0.24
1
0.66 0.86 0.51-1.45 0.56
0.08 0.72 0.56-0.93 0.01*
1
<0.001* 3.99 2.04-7.81 <0.001*
<0.001* 6.46 3.10-13.50 <0.001*
1
<0.001* 0.20 0.09-0.45 <0.001*
<0.001* 0.31 0.18-0.53 <0.001*
1
0.01* 0.61 0.39-0.96 0.03*
1
<0.001* 3.55 2.22-5.69 <0.001*
Table 3 Multivariable analysis of overall survival in patients with middle ear cancer
Full model Reduced model
Covariate HR 95% CI P-value HR 95% CI P-value
Age (70:45) 2.05 1.50-2.80 <0.001* 2.07 1.52-2.82 <0.001*
Sex
Male 1 -
Female 1.17 0.82-1.67 0.38 - - -
Race
White 1 -
Non White 1.11 0.73-1.68 0.64 - - -
Year of diagnosis (2000:1990) 0.89 0.70-1.14 0.35 - - -
Stage
Localized 1 1
Regional 2.01 1.23-3.28 0.005* 2.00 1.22-3.25 0.01*
Distant 3.47 1.94-6.22 <0.001* 3.46 1.93-6.19 <0.001*
Radiation
No 1 1
Yes 1.52 1.00-2.30 0.05 1.66 1.12-2.46 0.01*
Histological types# - - <0.001* - - <0.001*
Surgery# - - 0.02* - - 0.02*
Histology × surgery - - 0.01* - - 0.01*
Surgery
Squamous cell carcinoma 1 1
Adenocarcinoma 0.23 0.11-0.47 <0.001* 0.24 0.12-0.50 <0.001*
Others 0.67 0.39-1.17 0.15 0.70 0.40-1.20 0.20
No surgery
Squamous cell carcinoma 1 1
Adenocarcinoma 1.97 0.55-7.11 0.29 2.21 0.61-7.93 0.22
Others 0.57 0.25-1.27 0.16 0.58 0.26-1.28 0.18
Abbreviations: HR Hazard Ratio, CI Confidence Interval.
#Hazard ratios for histology type are presented by surgery because of the significant interaction between these two covariates.
*P <0.05.
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The nomograms were developed for predicting OS and
CSS based on beta coefficients in finial models (Figure 2).
To use the nomogram, first draw a vertical line up to
the points row to assign points for each variable, then
add up the points for each variable to obtain the total
points, and drop a vertical line from the total points row
to obtain the 5- and 10-year survival.
Model performance was evaluated by internal validation
with bootstrapping. The discrimination (bootstrap-cor-
rected concordance index) was 0.73 for model predicting
OS, and 0.74 for CSS. This implies that the models are
reasonably accurate. The calibration plots are shown in
Figure 3. Points in both plots close to the 45-degree
line show good agreement between predicted and
observed outcomes.Discussion
We estimated the survival of primary middle ear cancer
and developed prognostic models to predict 5-year OS
and CSS using a SEER dataset. Simple nomograms were
constructed based on the prognostic model, which
included five variables available from the cancer registry
or routine clinical practice.
Individual estimation of survival probability for cancer
patients is useful for treatment selection and clinical coun-
seling. An individual predictive value of prognosis can also
be used to identify and stratify patients for clinical trials. A
nomogram based on a statistical model provides clinicians
and patients with a practical tool for prognostic prediction
[9]. A number of important cancer prognostic models and
nomograms have been developed and are in use today
for prostate, pancreas, breast, and thyroid cancer and
Table 4 Multivariable analysis of cause-specific survival in patients with middle ear cancer
Full model Reduced model
Covariate HR 95% CI P-value HR 95% CI P-value
Age (70:45) 1.66 1.16-2.38 0.004* 1.70 1.19-2.45 0.002*
Sex
Male 1 -
Female 1.37 0.89-2.11 0.15 - - -
Race
White 1 -
Non White 0.80 0.47-1.38 0.42 - - -
Year of diagnosis (2000:1990) 0.80 0.61-1.05 0.11 - - -
Stage
Localized 1 1
Regional 2.93 1.43-6.00 0.003* 2.93 1.43-5.99 0.003*
Distant 4.88 2.20-10.82 <0.001* 4.82 2.17-10.69 <0.001*
Radiation
No 1 1
Yes 1.84 1.07-3.15 0.03* 2.14 1.28-3.58 0.004*
Histological types# - - 0.003* - - 0.004*
Surgery# - - 0.06 - - 0.05
Histology × surgery - - 0.03* - - 0.02*
Surgery
Squamous cell carcinoma 1 1
Adenocarcinoma 0.16 0.06-0.46 <0.001* 0.18 0.06-0.50 0.001*
Others 0.55 0.27-1.12 0.10 0.60 0.30-1.19 0.15
No surgery
Squamous cell carcinoma 1 1
Adenocarcinoma 1.95 0.40-9.51 0.41 2.33 0.47-11.68 0.30
Others 0.51 0.19-1.39 0.19 0.54 0.20-1.46 0.22
Abbreviations: HR Hazard Ratio, CI Confidence Interval.
#Hazard ratios for histology type are presented by surgery because of the significant interaction between these two covariates.
*P <0.05.
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nomogram is the first to use the SEER database to predict
the prognosis of middle ear cancer.
Because of the rarity of middle ear cancer, evaluation of
prognosis can be challenging. Most of the literature has
reported results combining malignancies of external audi-
tory canal with primary tumors of the middle ear. So far,
middle ear cancer as a subgroup of malignant tumor of
the temporal bone has not been well studied. In addition,
most published studies involving the temporal bone ori-
ginate from the experiences of single institutions and the
results are heterogeneous. Due to the short follow-up
periods and rare cases and events, reports from a single
institution often do not have sufficient power to identify
true prognostic factors. A population-based study can pro-
vide more reliable analysis, and the results are likely to be
more generally applicable. The SEER data are a powerfultool for exploring prognostic factors, especially for
unusual and rare tumors.
The simplicity of our prognostic model is also a strength.
In clinical practice, complex models may not be well
accepted and implemented. Our nomogram is based on few
predictors, which are all available from routine clinical
work. We therefore believe that it can be easily used by cli-
nicians to make accurate individualized prognosis estimates.
Richard first reported the prognosis of middle ear cancer
using the SEER database [2], showing 5-year OS by stage,
histology and treatment of patients diagnosed between
1973 and 2004. However, only univariate analysis was con-
ducted in Richard’s study. In this article, we updated their
results to 2011 and added multivariable models and
nomograms to predict OS and CSS.
Stage was found to be an independent prognosis factor of
overall survival, with local patients having better survival
Figure 2 Nomograms for predicting 5- and 10-year overall survival and cause-specific survival. (A) Prediction for overall survival; (B)
Prediction for cause-specific survival. Abbreviations: Stage: L, localized; R, regional; D, distant. Histological subtype: S, squamous cell carcinoma;
A, adenocarcinoma; O, others. Instructions: Locate the patient’s characteristic on the variable row and draw a vertical line straight up to the points
row to assign a value of points for the variable. Repeat this process to obtain points for each variable. Add up the total points and drop a vertical
line from the total points row to obtain the 5- and 10-year survival.
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ging system currently used for temporal bone malig-
nancy, such as the Pittsburgh staging system, which
provides a comprehensive means of assessing temporal
bone tumors according to imaging and preoperative
clinical information. The Pittsburgh staging system is
based on external auditory canal malignancies, [1] and
therefore was not suitable for staging cancer in this
study. Stell and McCormick proposed a staging system
in 1985 that can be used for staging both external audi-
tory canal and middle ear cancer [16]. Nevertheless, the
Stell and McCormick staging system also could not be
used in this study because of the limited SEER dataset.
Surgical resection with the purpose of achieving a nega-
tive margin and decreasing morbidity or mortality is con-
sidered to be the standard of care for middle ear cancer. It
is agreed that all patients who are able to tolerate an ope-
ration should be treated with surgery, except those who
are diagnosed with histiocytosis X, which is treated pri-
marily with radiation only or adjuvant chemotherapy [1].
Surgical approaches used in clinical practice include local
canal resection, sleeve resection, en bloc resection of theexternal auditory canal, lateral temporal bone resection,
subtotal temporal bone resection and total temporal bone
resection [17]. Whether radical surgery is necessary
remains under debate [1]. Unfortunately, SEER does not
provide data regarding the detailed surgical approach and
margin status. Further evaluation of the surgical manage-
ment of middle ear cancer needs other cohorts or series.
Radiotherapy is advocated as an adjunct to surgery or
for palliation, rather than as a curative approach. T2 and
higher-staged tumors, recurrent tumors, positive margins,
perineural spread, positive lymph nodes, or extracapsular
spread are indications for postoperative radiotherapy. The
effectiveness of adjuvant radiation remains controversial.
Some studies have demonstrated an improvement in
terms of the survival rate and local control in patients with
positive surgical margins who underwent adjuvant radio-
therapy compared with patients who underwent surgery
only [18-20]. In contrast, other authors concluded that a
positive surgical margin was the major cause of recur-
rence, and adjuvant radiotherapy showed no more effect
on survival [21-23]. Results of our study suggested that
radiotherapy may be an adverse prognostic factor for
Figure 3 Calibration plots. (A) Overall survival; (B) Cause-specific survival. The grey line represents the “ideal” line of a perfect match between
predicted and observed survival. Dots correspond to apparent predictive accuracy. X marks the bootstrap corrected estimates.
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operable disease, co-morbid disease, or a positive surgical
margin; thus, their prognosis was worse. Because this
study was limited to the predictive factors available from
the SEER database, these factors could not be adjusted in
the current model. New sources of data which consider a
more detailed extent of disease or stage will be important
to address this issue. Furthermore, due to the lack of data
on local recurrence, the survival benefit of adjuvant radio-
therapy for loco-regional control may have been missed.
There are several limitations of this study. First, some
factors impacting survival are not included in our models.
For example, it appears that positive margins and promon-
tory or facial nerve involvement are negative prognostic
markers. However, this surgical information cannot be
found in the SEER registry. In addition, chemotherapy
data cannot be obtained from the public SEER database.
Second, patients were enrolled in the database over three
decades. It is therefore possible that improvements in
multiplanar imaging, Intensity Modulated Radiation The-
rapy (IMRT), and chemotherapy, along with advances in
skull base surgical techniques have combined to improve
overall survival. We did not use the full model to build the
nomogram, which was adjusted for the year of diagnosis.
After model selection, the year of diagnosis showed drop
outs. Thus, our final models and nomograms might have a
low estimate of survival probability. Although this low es-
timate of prognosis might exist, it was not serious because
over 60% of patients in the study cohort enrolled after
2000. Finally, we used internal validation in the model due
to the relatively small sample size. Examination of the
apparent accuracy of a multivariable model using the
training dataset results in optimistically biased perfor-
mance [24], and the potential for optimism in model per-
formance increases when the number of events decreases
and the number of candidate predictors increases [25]. Athere, we used the bootstrapping technique to obtain a nearly
unbiased internal assessment of accuracy. However, it is not
enough to demonstrate a good performance of a model on
the development dataset only, even after corrections from
bootstrapping [26], external validation is still need to confirm
whether our nomograms can be generalized to a new patient
population. Despite its limitations, SEER still provides the
largest cohort of middle ear cancer patients available, which
is a valuable resource for providing valid statistical compari-
son and building predictive models for this rare lesion.
Conclusions
In conclusion, we analyzed prognostic data on middle
cancer using the SEER database, a high quality reliable
cancer cohort. Survival outcome specific to histology,
stage, surgery, radiation therapy and other prognostic
factors are described. We then built survival models to
predict 5- and 10-year OS and CSS. The models provide
objective analysis of all currently available data. The
performance of the models is good, with a c-index of
0.73 and 0.74 for models predicting OS and CSS. These
nomograms should thus be considered as an accurate
tool to predict the clinical prognosis.
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